News
Biocept Looking to Redefine CTC Dx Market, Plans Product Launch - 8/30/2010
Biocept's Go Ahead with Plans to Launch a Viable Product in the Fall, with More to Follow.
Biocept Targets Spreading Tumors with Advance in Diagnostics - 8/20/2010
Biocept, Inc. Pioneers Revolutionary Diagnostics Aimed at Personalized Cancer Management
Biocept, Inc. Announces Two New Director Appointments - July 1, 2009
Biocept, Inc. ("Biocept"), an emerging leader in biotechnology, announced today the appointment of Daniel H. Petree and M. Faye Wilson as Directors.
Biocept Awarded Accreditation by the College of American Pathologists - December 3, 2008
Biocept, Inc. ("Biocept"), an emerging leader in biotechnology, announced today their CLIA laboratory has been awarded accreditation by the Commission on Laboratory Accreditation of the College of American Pathologists (CAP), based on the results of a recent on-site inspection.
Biocept, Inc. Announces CEO and Director Appointments - October 6, 2008
Biocept, Inc. ("Biocept"), an emerging leader in biotechnology, announced today the appointment of Stephen M. Coutts, Ph.D. as CEO, President and Director and the appointment of Edward A. Dennis, Ph.D., as Director. Biocept also announced the resignation of its former CEO, President and Director, Gordon F. Janko.
Biocept Announces Study to Isolate Circulating Tumor Cells from Blood - December 3, 2007
Biocept, an emerging leader in biotechnology, is initiating a collaborative study with the University of Texas M.D. Anderson Cancer Center to investigate the ability to isolate circulating tumor cells (CTCs) in blood. The study will use Biocept's proprietary CEE(TM) (Cell Enrichment and Extraction) technology, designed to capture rare cells from a larger heterogeneous cell population. The focus of this study is ovarian cancer.
